Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

U032 - Treating Alopecia Areata, Vitiligo and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology

Sunday, July 29; 7:30 AM - 8:30 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify and describe a new class of medications that will be useful in dermatology
  • Utilize JAK inhibitors for the treatment of alopecia areata, vitiligo and atopic dermatitis
  • Summarize the potential adverse effects of JAK inhibitors


Effective treatments for alopecia areata, vitiligo and atopic dermatitis are limited. The recent development of Janus kinase inhibitors has led to new therapeutic options in dermatology. The application of Janus kinase inhibitors to three common dermatologic diseases will be presented, including the results of clinical trials and case series. Safety will be discussed. The audience for this session will be dermatologists whose practice involves the care of patients with these common dermatoses.


  • King, Brett Andrew, MD, PhD: Concert Pharmaceuticals – C(Fees), I(Fees); Dermavant Sciences – A(H); Eli Lilly and Company – C(Fees), I(Fees); Pfizer Inc. – A(Fees), A(H), C(Fees), I(Fees); Regeneron – SP(H);
Event Details
  • Date
    Sunday, July 29
  • Time
    7:30 AM - 8:30 AM
  • Location
    Regency Ballroom B
  • CME Credits
  • Type
  • Brett Andrew King, MD, PhD, FAAD